Edwards Lifesciences (EW) is trading sharply higher today (up about 5.6% to around $83.68) after the company reported first-quarter 2026 results that came in ahead of expectations and raised key elements of its 2026 outlook. The guidance increase is being read as a confidence signal that structural heart procedure demand and Edwards’ execution—particularly in transcatheter aortic valve replacement (TAVR)—are holding up better than investors had feared. (edwards.com)

For Q1 2026 (ended March 31, 2026), Edwards reported GAAP EPS of $0.66 and adjusted EPS of $0.78. The company raised its full-year 2026 constant-currency sales growth guidance to 9%–11% (from 8%–10%) and lifted its full-year 2026 TAVR sales growth guidance to 7%–9% (from 6%–8%). For Q2 2026, Edwards guided total sales of $1.66–$1.74 billion and adjusted EPS of $0.70–$0.76, helping extend the post-earnings momentum into today’s session. (edwards.com)

The rally reflects investors re-pricing Edwards’ 2026 trajectory around stronger near-term TAVR performance and a higher companywide growth floor, which can support margin leverage expectations over time. The company also highlighted capital return activity, including an accelerated share repurchase agreement to buy back $500 million in shares, which can add support to sentiment alongside improving fundamentals. (edwards.com)